MedTrace Logo

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

NCT01677065 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2018-09-28

No results posted yet for this study

Summary

To determine whether the bioavailability of the controlled-release test formulation is at least as high as that for the commercial reference drug.

Conditions

  • Healthy

Interventions

DRUG

Oxycodone controlled-release test formulation

single dose administration of test formulation under fasted conditions

DRUG

Immediate-release reference drug

single dose administration of reference drug under fasted conditions

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01677065 on ClinicalTrials.gov